VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Lanadelumab Injection [Takhzyro]
Phase 2
V
Vanderbilt University Medical Center
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[2]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hemodialysis Complication
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hemodialysis Complication
Phase 2
Completed
Clinical
Trials by Indication
[1]
Hemodialysis Complication
1 trial
Prevention of Dialysis-Induced Hypotension by Inhibiting Plasma Kallikrein
Completed
·
V
Vanderbilt University Medical Center
·
Phase 2
·
NCT05297786
·
28 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Lanadelumab Injection [Takhzyro]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform
—
Drug–disease associations for Lanadelumab Injection [Takhzyro]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR
—
Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Highest Phase
Phase 2
[1]
Company
V
Vanderbilt University Medical Center
Related News